Blood pressure management in patients with type 2 diabetes mellitus

Abstract

Hypertension aggravates macrovascular and microvascular diseases and mortality in patients with type 2 diabetes mellitus (T2DM). The current Japanese Society of Hypertension Guidelines of the Management of Hypertension (JSH 2014) recommends that antihypertensive medication should be initiated concomitantly with lifestyle modification when blood pressure (BP) is 130/80 mm Hg and that target levels of office and home BP should be <130/80 mm Hg and <125/75 mm Hg, respectively, in T2DM patients. Considering more favorable metabolic profiles and renoprotective effects than other classes of antihypertensive agents, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are recommended as the first-line therapy for patients with hypertension and T2DM in JSH 2014. However, the target BP and the first-line therapy remain controversial because of the paucity of high-quality evidence with consistency. It is suggested that BP management should be tailored for each patient with T2DM, based on tolerability and considerations of comorbidity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. 1

    Gillespie CD, Hurvitz KA . Prevalence of hypertension and controlled hypertension in the United States, 2007-2010. MMWR Suppl 2013; 62: 144–148.

    PubMed  Google Scholar 

  2. 2

    Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL . Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–912.

    CAS  Article  Google Scholar 

  3. 3

    Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–419.

    CAS  Article  Google Scholar 

  4. 4

    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–713.

    Article  Google Scholar 

  5. 5

    Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.

    CAS  Article  Google Scholar 

  6. 6

    ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

    Article  Google Scholar 

  7. 7

    Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S . Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410–1418.

    CAS  Article  Google Scholar 

  8. 8

    Horr S, Nissen S . Managing hypertension in type 2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2016; 30: 445–454.

    Article  Google Scholar 

  9. 9

    Brunström M, Eliasson M, Nilsson PM, Carlberg B . Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews. J Hypertens 2017; 35: 453–462.

    Article  Google Scholar 

  10. 10

    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW . The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–652.

    CAS  Article  Google Scholar 

  11. 11

    Schrier RW, Estacio RO, Esler A, Mehler P . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–1097.

    Article  Google Scholar 

  12. 12

    Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3–107.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13

    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    CAS  Article  Google Scholar 

  14. 14

    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.

    CAS  Article  Google Scholar 

  15. 15

    Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575–1585.

    Article  Google Scholar 

  16. 16

    Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ . Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–68.

    CAS  Article  Google Scholar 

  17. 17

    Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S . Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012; 59: 74–83.

    Article  Google Scholar 

  18. 18

    Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P . Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens 2011; 29: 1253–1269.

    CAS  Article  Google Scholar 

  19. 19

    Bangalore S, Kumar S, Lobach I, Messerli FH . Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799–2810.

    CAS  Article  Google Scholar 

  20. 20

    Mancia G, Fagard R, Narkiewicz K, Redo'n J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F . 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.

    CAS  Article  Google Scholar 

  21. 21

    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–520.

    CAS  Article  Google Scholar 

  22. 22

    American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl 1): S14–S80.

    Article  Google Scholar 

  23. 23

    Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y . Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010; 41: 203–209.

    CAS  Article  Google Scholar 

  24. 24

    Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Okayama A, Okamura T . New diagnosis criteria for diabetes with hemoglobin A1c and risks of macro-vascular complications in an urban Japanese cohort: the Suita study. Diabetes Res Clin Pract 2010; 88: e20–e23.

    Article  Google Scholar 

  25. 25

    Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N . Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). Clin Endocrinol Metab 2011; 96: 3448–3456.

    CAS  Article  Google Scholar 

  26. 26

    Onishi H, Saito S, Shimamoto K . Tanno-Sobetsu Study review in 2007. Ther Res 2007; 28: 513–525 (in Japanese).

    Google Scholar 

  27. 27

    Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253–392.

    Article  Google Scholar 

  28. 28

    Noguchi Y, Asayama K, Staessen JA, Inaba M, Ohkubo T, Hosaka M, Satoh M, Kamide K, Awata T, Katayama S, Imai Y . Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes. J Hypertens 2013; 31: 1593–1602.

    CAS  Article  Google Scholar 

  29. 29

    American Diabetes Association. Cariovascular disease and risk manegement. Diabetes Care 2015; 38: S49–S57.

    Article  Google Scholar 

  30. 30

    Xiao WY, Ning N, Tan MH, Jiang XS, Zhou L, Liu L, Yi D, Wei P . Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. Hypertens Res 2016; 39: 321–326.

    Article  Google Scholar 

  31. 31

    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.

    Article  Google Scholar 

  32. 32

    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

    CAS  Article  Google Scholar 

  33. 33

    Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T . Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393–398.

    CAS  Article  Google Scholar 

  34. 34

    Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G . Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951.

    CAS  Article  Google Scholar 

  35. 35

    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

    CAS  Article  Google Scholar 

  36. 36

    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I . Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

    CAS  Article  Google Scholar 

  37. 37

    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.

    CAS  Article  Google Scholar 

  38. 38

    Viberti G, Wheeldon NM . Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–678.

    CAS  Article  Google Scholar 

  39. 39

    Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S . Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577–1578.

    CAS  Article  Google Scholar 

  40. 40

    Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion Júnior D, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Gallois Y, Amouyel P, Ollivier JP, Asmar R . Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613–1622.

    CAS  Article  Google Scholar 

  41. 41

    Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, Twisk JW, Stehouwer CD . Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19: 429–437.

    CAS  Article  Google Scholar 

  42. 42

    UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.

    Article  Google Scholar 

  43. 43

    Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K . Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543–1549.

    CAS  Article  Google Scholar 

  44. 44

    Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H . Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621–626.

    CAS  Article  Google Scholar 

  45. 45

    Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K . Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321–326.

    Article  Google Scholar 

  46. 46

    Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T . Renal-protective effect of T- and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 2007; 30: 797–806.

    CAS  Article  Google Scholar 

  47. 47

    Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes. Lancet 2005; 366: 2026–2033.

    CAS  Article  Google Scholar 

  48. 48

    Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A . Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091–2096.

    CAS  Article  Google Scholar 

  49. 49

    Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R . Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677–684.

    CAS  Article  Google Scholar 

  50. 50

    Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S . Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.

    CAS  Article  Google Scholar 

  51. 51

    Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P . Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303–1309.

    CAS  Article  Google Scholar 

  52. 52

    Derosa G, Querci F, Franzetti I, Dario Ragonesi P, D'Angelo A, Maffioli P . Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. Hypertens Res 2015; 38: 690–694.

    CAS  Article  Google Scholar 

  53. 53

    Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B . Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56: 77–85.

    CAS  Article  Google Scholar 

  54. 54

    Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA . Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31: 2094–2102.

    CAS  Article  Google Scholar 

  55. 55

    Saito A . The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res 2015; 38: 367–374.

    Article  Google Scholar 

  56. 56

    Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

    CAS  Article  Google Scholar 

  57. 57

    Fried LF, Emanuelle N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892–1903.

    CAS  Article  Google Scholar 

  58. 58

    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA . Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–2213.

    CAS  Article  Google Scholar 

  59. 59

    Wu Z, Jin C, Vaidya A, Jin W, Huang Z, Wu S, Gao X . Longitudinal patterns of blood pressure, incident cardiovascular events, and all-cause mortality in normotensive diabetic people. Hypertension 2016; 68: 71–77.

    CAS  Article  Google Scholar 

  60. 60

    Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ . Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884–893.

    Article  Google Scholar 

  61. 61

    Kai H, Ueno T, Kimura T, Adachi H, Furukawa Y, Kita T, Imaizumi T . Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. J Hypertens 2011; 29: 1889–1896.

    CAS  Article  Google Scholar 

  62. 62

    Kai H, Kimura T, Fukuda K, Fukumoto Y, Kakuma T, Furukawa Y . Impact of low diastolic blood pressure on risk of cardiovascular death in elderly patients with coronary artery disease after revascularization - The CREDO-Kyoto Registry Cohort-1. Circ J 2016; 80: 1232–1241.

    CAS  Article  Google Scholar 

  63. 63

    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R . Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256–263.

    CAS  Article  Google Scholar 

  64. 64

    Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr . Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43–50.

    CAS  Article  Google Scholar 

  65. 65

    Tsujimoto T, Sugiyama T, Noda M, Kajio H . Intensive glycemic therapy in type 2 diabetes patients on β-blockers. Diabetes Care 2016; 39: 1818–1826.

    CAS  Article  Google Scholar 

  66. 66

    Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F . Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997; 126: 955–959.

    CAS  Article  Google Scholar 

  67. 67

    Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT . A randomized trial of intensive vs. standard blood-pressure control. N Engl J Med 2015; 373: 2103–2116.

    CAS  Article  Google Scholar 

  68. 68

    Brunström M, Carlberg B . Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352: i717.

    Article  Google Scholar 

  69. 69

    Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A . Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603–615.

    Article  Google Scholar 

  70. 70

    Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, Rosengren A, Svensson AM, Miftaraj M, Franzén S, Björck S . Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ 2016; 354: i4070.

    Article  Google Scholar 

  71. 71

    American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 2017; 40 (Suppl 1): S75–S87.

    Article  Google Scholar 

  72. 72

    Bangalore S, Fakheri R, Toklu B, Messerli FH . Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016; 352: i438.

    Article  Google Scholar 

  73. 73

    Grossman A, Grossman E . Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol 2017; 16: 3.

    Article  Google Scholar 

  74. 74

    Tikkanen I, Chilton R, Johansen OE . Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens 2016; 25: 81–86.

    CAS  Article  Google Scholar 

  75. 75

    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

    CAS  Article  Google Scholar 

  76. 76

    Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ . SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1333–1339.

    Article  Google Scholar 

  77. 77

    Kimura G . Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J 2016; 80: 2277–2281.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by JSPS KAKENHI Grant number 16K09468.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hisashi Kai.

Ethics declarations

Competing interests

HK has received lecture fees from Daiichi Sankyo, Mitsubishi Tanabe Pharma, MSD KK, Sumitomo Dainippon Pharma, Takeda Pharmaceutical and Toa Eiyo.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kai, H. Blood pressure management in patients with type 2 diabetes mellitus. Hypertens Res 40, 721–729 (2017). https://doi.org/10.1038/hr.2017.55

Download citation

Keywords

  • antihypertensive therapy
  • blood pressure target
  • cardiovascular outcomes
  • first-line treatment
  • mortality

Further reading

Search